WallStreetZenWallStreetZen

NASDAQ: HYFT
Mindwalk Holdings Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HYFT

Based on 1 analyst offering 12 month price targets for Mindwalk Holdings Corp

Min Forecast
$5.00+303.23%
Avg Forecast
$5.00+303.23%
Max Forecast
$5.00+303.23%

Should I buy or sell HYFT stock?

Based on 1 analyst offering ratings for Mindwalk Holdings Corp.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although HYFT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates HYFT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their HYFT stock forecasts and price targets.

HYFT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-16

1 of 1

Forecast return on equity

Is HYFT forecast to generate an efficient return?

Company
N/A
Industry
73.29%
Market
160.77%

Forecast return on assets

Is HYFT forecast to generate an efficient return on assets?

Company
N/A
Industry
30.71%

HYFT earnings per share forecast

What is HYFT's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.31
Avg 2 year Forecast
-$0.26
Avg 3 year Forecast
-$0.17

HYFT revenue forecast

What is HYFT's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$16.2M+21.18%
Avg 2 year Forecast
$20.9M+56.24%
Avg 3 year Forecast
$26.9M+101.28%
HYFT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HYFT revenue growth forecast

How is HYFT forecast to perform vs Biotechnology companies and vs the US market?

Company
25.65%
Industry
36.28%
Market
14.1%
HYFT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HYFT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HYFT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HYFT$1.24$5.00+303.23%Strong Buy
GRML$0.48N/AN/A
INKT$11.60$35.00+201.72%Buy
PDSB$1.00$9.00+800.00%Strong Buy
CING$5.25$34.50+557.14%Strong Buy
View Top Biotech Stocks

Mindwalk Holdings Stock Forecast FAQ

Is Mindwalk Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HYFT) stock is to Strong Buy HYFT stock.

Out of 1 analyst, 1 (100%) are recommending HYFT as a Strong Buy, 0 (0%) are recommending HYFT as a Buy, 0 (0%) are recommending HYFT as a Hold, 0 (0%) are recommending HYFT as a Sell, and 0 (0%) are recommending HYFT as a Strong Sell.

If you're new to stock investing, here's how to buy Mindwalk Holdings stock.

What is HYFT's earnings growth forecast for 2026-2028?

(NASDAQ: HYFT) Mindwalk Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.

Mindwalk Holdings's earnings in 2026 is -$9,003,676.On average, 5 Wall Street analysts forecast HYFT's earnings for 2026 to be -$14,611,472, with the lowest HYFT earnings forecast at -$14,648,841, and the highest HYFT earnings forecast at -$14,223,763. On average, 4 Wall Street analysts forecast HYFT's earnings for 2027 to be -$12,149,756, with the lowest HYFT earnings forecast at -$12,817,736, and the highest HYFT earnings forecast at -$11,280,916.

In 2028, HYFT is forecast to generate -$8,099,838 in earnings, with the lowest earnings forecast at -$8,697,749 and the highest earnings forecast at -$7,357,119.

What is HYFT's revenue growth forecast for 2026-2028?

(NASDAQ: HYFT) Mindwalk Holdings's forecast annual revenue growth rate of 25.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.1%.

Mindwalk Holdings's revenue in 2026 is $13,547,058.On average, 5 Wall Street analysts forecast HYFT's revenue for 2026 to be $755,751,280, with the lowest HYFT revenue forecast at $718,708,770, and the highest HYFT revenue forecast at $784,759,349. On average, 4 Wall Street analysts forecast HYFT's revenue for 2027 to be $974,362,813, with the lowest HYFT revenue forecast at $933,863,625, and the highest HYFT revenue forecast at $1,005,472,916.

In 2028, HYFT is forecast to generate $1,255,287,975 in revenue, with the lowest revenue forecast at $1,194,469,125 and the highest revenue forecast at $1,304,662,417.

What is HYFT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: HYFT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.71%.

What is HYFT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HYFT price target, the average HYFT price target is $5.00, with the highest HYFT stock price forecast at $5.00 and the lowest HYFT stock price forecast at $5.00.

The Wall Street analyst predicted that Mindwalk Holdings's share price could reach $5.00 by Apr 16, 2027. The average Mindwalk Holdings stock price prediction forecasts a potential upside of 303.23% from the current HYFT share price of $1.24.

What is HYFT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: HYFT) Mindwalk Holdings's current Earnings Per Share (EPS) is -$0.20. On average, analysts forecast that HYFT's EPS will be -$0.31 for 2026, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at -$0.30. On average, analysts forecast that HYFT's EPS will be -$0.26 for 2027, with the lowest EPS forecast at -$0.27, and the highest EPS forecast at -$0.24. In 2028, HYFT's EPS is forecast to hit -$0.17 (min: -$0.19, max: -$0.16).

What is HYFT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: HYFT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.